Barry Kenny

Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK.

Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK.

Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK.

Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016.

Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK.

Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK.

Paradigm Therapeutics Ltd. discovers and develops drugs. The genomics-based drug discovery company uses research methods including model mouse genetics, bioinformatics and molecular biology to identify genes that serve as drug targets. The company has launched a subsidiary research center in Singapore. The company was founded in 1999 by Aparicio Samuel and Mark Carlton and is headquartered in Cambridge, UK.

Metrion Biosciences Ltd. is a contract research organization that specializes in providing drug discovery services to pharmaceutical and bioscience customers. Metrion Biosciences is based in Great Abington, UK and was founded in 2015. The British company offers a range of high-quality ion channel assays on a fee-for-service or collaboration basis, including an industry-leading panel of in vitro cardiac ion channel safety assays, translational native cell and phenotypic assays for neurological and cardiotoxicity testing, and a range of other ion channel screening services such as cell line development and optimization. Andrew Southan has been the CEO of the company since 2016.